Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-08
  • br Shariat S Badiee A

    2020-08-30


    Shariat, S., Badiee, A., Jalali, S.A., Mansourian, M., Yazdani, M., Mortazavi, S.A., Jaafari, M.R., 2014. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. Cancer Lett. 355, 54–60.
    Yuba, E., 2018. Liposome-based immunity-inducing systems for cancer immunotherapy.
    Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy. J. Cell.
    Zamani, P., Navashenaq, J.G., Nikpoor, A.R., Hatamipour, M., Oskuee, R.K., Badiee, A., Jaafari, M.R., 2019. MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. J. Control. Release.
    Contents lists available at ScienceDirect
    EBioMedicine
    Research paper
    Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β-catenin in cancer stem-like cells
    a Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital, National Centre for Liver Cancer, Second Military Medical University, Shanghai 200438, China
    b Department of Urinary Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Road No.2, Shanghai 200025, China
    Article history:
    Keywords:
    Prostate cancer
    Cancer stem like cell β-catenin
    Disease progression 
    Background: Cell division cycle 20 (CDC20) is frequently overexpressed in malignant tumours and involved in the differentiation process of hematopoietic stem cells. However, the role of CDC20 in prostate cancer stem-like Patulin (CSCs) remains poorly understood. Methods: The expression of CDC20, CD44, β-catenin were examined in prostate cancer specimens by immunohis-tochemistry assay, the role of CDC20 on the stem-like properties of prostate CSCs was accessed by real-time quantitive PCR, spheroid formation, in vitro and in vivo limiting dilution assay.
    Finding: CDC20 was associated with malignant progression of prostate cancer, the patients with both high ex-pression CDC20 and CD44 or β-catenin were associated with more aggressive clinicopathological features and poor prognosis. CDC20 was usually enriched in CD44+ prostate CSCs. Knockdown of CDC20 could inhibit the expression of stemness-related genes, self-renewal ability, chemo-resistance, invasion capability and tumorigenicity of CD44+ prostate CSCs. Mechanistically, CDC20 promoted degradation of Axin1, the core mem-ber of β-catenin destruction complex, sequentially reduced the phosphorylation of β-catenin, promoting the lat-ter into the nucleus, thereby enhancing the self-renewal capacity of CD44+ prostate CSCs.
    Interpretation: Our results indicated that CDC20 maintains the self-renewal ability of CD44+ prostate CSCs by pro-moting nuclear translocation and trans-activation of β-catenin. In addition, CDC20 combined with CD44 or β-catenin can serve as an important indicator for prognosis of patients with prostate cancer.
    © 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
    1. Introduction
    Prostate cancer is the first most frequently diagnosed malignancies and the second leading cause of cancer-related deaths among men in developed countries [1]. Although prostate cancer can often be cured at early stage [2], patients with metastasis have to go through androgen deprivation therapy (ADT) [3] and inevitably progress into a drug
    Corresponding author at: Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital, National Centre for Liver Cancer, Second Military Medical University, Shanghai 200438, China. Corresponding author at: Department of Urinary Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, No 197 Ruijin Second Road, Shanghai 200025, China.
    [email protected] (C. Su).
    1 These authors contributed equally to the study. 
    resistance stage called castration-resistant prostate cancer (CRPC), lead-ing to increased cancer-related deaths [4]. For patients with metastatic CRPC, docetaxel-based chemotherapy is recommended as one of the first-line treatments by multiple guidelines [5,6]. However, a limited survival benefit has been proven due to the chemo-resistance and re-lapse of prostate cancer, the mechanism underlying the resistance to docetaxel for metastatic CRPC, therefore, remains obscure.
    Increasing evidence has revealed that the critical role of cancer stem-like cells (CSCs) in chemo-resistance and relapse of prostate cancer [7,8]. The hypothesis of CSC suggests that tumours are maintained in the hierarchical tissues of cells, and that cancer stem cell-like cell sub-sets are essential for initiating and maintaining tumour growth due to their strong self-renewal capacity [9]. The presence of CSC was first identified in myeloid leukemia [10] and has recently been observed in various solid malignancies [11]. Concrete evidence indicated the impor-tance of prostate CSCs in tumorigenesis and anticancer drug resistance [12]. Previous studies identified several cell surface antigens to charac-terize prostate CSCs, such as CD44 [13–17], CD133 [18] and OV6 [19].